Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Max Schmauss

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Journal of Psychiatric Research|August 25, 2011
Influencing factors and predictors of early improvement in the acute treatment of schizophrenia and schizophrenia spectrum disorderRebecca Schennach-Wolff, Sebastian Meyer, Florian Seemüller, et al.
Psychiatric Services (Washington, D.C.)|January 10, 2012
Predictors of relapse in the year after hospital discharge among patients with schizophreniaRebecca Schennach, Michael Obermeier, Sebastian Meyer, et al.
European Archives of Psychiatry and Clinical Neuroscience|September 28, 2014
What are residual symptoms in schizophrenia spectrum disorder? Clinical description and 1-year persistence within a naturalistic trialRebecca Schennach, Michael Riedel, Michael Obermeier, et al.
Pharmacopsychiatry|May 16, 2017
Add-on Antidepressants in the Naturalistic Treatment of Schizophrenia Spectrum Disorder - When, Who, and How?Rebecca Schennach, Michael Obermeier, Florian Seemüller, et al.
Journal of Clinical Psychopharmacology|November 25, 2010
Does clinical judgment of baseline severity and changes in psychopathology depend on the patient population? Results of a CGI and PANSS linking analysis in a naturalistic studyRebecca Schennach-Wolff, Michael Obermeier, Florian Seemüller, et al.
European Archives of Psychiatry and Clinical Neuroscience|August 30, 2019
What happens with schizophrenia patients after their discharge from hospital? Results on outcome and treatment from a "real-world" 2-year follow-up trialRebecca Schennach, Michael Riedel, Michael Obermeier, et al.
International Journal of Methods in Psychiatric Research|July 17, 2015
Challenging the understanding of significant improvement and outcome in schizophrenia - the concept of reliable and clinically significant change methodsRebecca Schennach, Hans-Jürgen Möller, Michael Obermeier, et al.
Schizophrenia Research|May 30, 2019
Remission in schizophrenia - What are we measuring? Comparing the consensus remission criteria to a CGI-based definition of remission and to remission in major depressionRebecca Schennach, Michael Obermeier, Ilja Spellmann, et al.
Bjpsych Open|October 18, 2021
Interplay between the genetics of personality traits, severe psychiatric disorders and COVID-19 host genetics in the susceptibility to SARS-CoV-2 infectionUrs Heilbronner, Fabian Streit, Thomas Vogl, et al.
Bjpsych Open|November 18, 2021
Interplay between the Genetics of Personality Traits, severe Psychiatric Disorders, and COVID-19 Host Genetics in the Susceptibility to SARS-CoV-2 Infection - ADDENDUMUrs Heilbronner, Fabian Streit, Thomas Vogl, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Journal of Psychiatric Research|August 25, 2011
Influencing factors and predictors of early improvement in the acute treatment of schizophrenia and schizophrenia spectrum disorderRebecca Schennach-Wolff, Sebastian Meyer, Florian Seemüller, et al.
Psychiatric Services (Washington, D.C.)|January 10, 2012
Predictors of relapse in the year after hospital discharge among patients with schizophreniaRebecca Schennach, Michael Obermeier, Sebastian Meyer, et al.
European Archives of Psychiatry and Clinical Neuroscience|September 28, 2014
What are residual symptoms in schizophrenia spectrum disorder? Clinical description and 1-year persistence within a naturalistic trialRebecca Schennach, Michael Riedel, Michael Obermeier, et al.
Pharmacopsychiatry|May 16, 2017
Add-on Antidepressants in the Naturalistic Treatment of Schizophrenia Spectrum Disorder - When, Who, and How?Rebecca Schennach, Michael Obermeier, Florian Seemüller, et al.
Journal of Clinical Psychopharmacology|November 25, 2010
Does clinical judgment of baseline severity and changes in psychopathology depend on the patient population? Results of a CGI and PANSS linking analysis in a naturalistic studyRebecca Schennach-Wolff, Michael Obermeier, Florian Seemüller, et al.
European Archives of Psychiatry and Clinical Neuroscience|August 30, 2019
What happens with schizophrenia patients after their discharge from hospital? Results on outcome and treatment from a "real-world" 2-year follow-up trialRebecca Schennach, Michael Riedel, Michael Obermeier, et al.
International Journal of Methods in Psychiatric Research|July 17, 2015
Challenging the understanding of significant improvement and outcome in schizophrenia - the concept of reliable and clinically significant change methodsRebecca Schennach, Hans-Jürgen Möller, Michael Obermeier, et al.
Schizophrenia Research|May 30, 2019
Remission in schizophrenia - What are we measuring? Comparing the consensus remission criteria to a CGI-based definition of remission and to remission in major depressionRebecca Schennach, Michael Obermeier, Ilja Spellmann, et al.
Bjpsych Open|October 18, 2021
Interplay between the genetics of personality traits, severe psychiatric disorders and COVID-19 host genetics in the susceptibility to SARS-CoV-2 infectionUrs Heilbronner, Fabian Streit, Thomas Vogl, et al.
Bjpsych Open|November 18, 2021
Interplay between the Genetics of Personality Traits, severe Psychiatric Disorders, and COVID-19 Host Genetics in the Susceptibility to SARS-CoV-2 Infection - ADDENDUMUrs Heilbronner, Fabian Streit, Thomas Vogl, et al.
Pageof 5